Presence of a p70 IL-2-binding peptide on leukemic cells from various hemopoietic lineages.
Recent studies have shown that IL-2R are composed of at least two polypeptide chains of 55 kDa (Tac or alpha-chain) and 70 to 75 kDa (p70 or beta-chain). The association of both chains forms high affinity IL-2R, whereas each chain alone binds IL-2 with a low (alpha-chain) or intermediate (beta-chain) affinity. So far, the p70 peptide has been found, in the absence of the Tac peptide, on the surface of lymphoid cells of T, B, or NK lineage. In this study, we investigated whether leukemic cells of various hemopoietic lineages expressed the p70 IL-2-binding protein. We found that both fresh leukemic cells obtained from patients, and cells from established leukemic lines of T cells, B cell, and myeloid origin constitutively expressed a p70 IL-2-binding protein on their surface, as detected by affinity cross-linking of radioiodinated IL-2. IL-2 binding and cross-linking to these cells was completely inhibited in the presence of an excess unlabeled rIL-2, but not with an anti-Tac mAb. Binding experiments on pre-B and myeloid cell lines revealed intermediate affinity IL-2R, whereas both high and intermediate affinity IL-2R were detected in T leukemic cells. The intermediate affinity binding of 125I-rIL-2 to the leukemic cell lines MOLT4 and Reh6 was inhibited by the TU27 mAb, which recognized the p75 chain of IL-2R. Moreover, the TU27 mAb could stain the K562, KM3, and MOLT4 (weakly) cell lines by indirect immunofluorescence. A high dose of rIL-2 (400 U/ml) enhanced the proliferation of cells from one out of three patients with acute myeloblastic leukemia, but it did not induce differentiation of the cells in any of three cases. Thus the finding of p70 IL-2-binding molecules on immature lymphoid and nonlymphoid hemopoietic cells should disclose new biologic functions for IL-2.
Allouche
M
M
Unité d'Oncogénèse Appliquée, INSERM U 268, Villejuif, France.
Sahraoui
Y
Y
Augery-Bourget
Y
Y
Ohashi
Y
Y
Sugamura
K
K
Jasmin
C
C
Georgoulias
V
V
D002454:Cell Differentiation; D002460:Cell Line; D003432:Cross-Linking Reagents; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D007938:Leukemia / Q000378:metabolism*; D015448:Leukemia, B-Cell / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology; D015458:Leukemia, T-Cell / Q000378:metabolism; D008565:Membrane Proteins / Q000032:analysis / Q000378:metabolism; D008970:Molecular Weight; D010455:Peptides / Q000032:analysis* / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000032:analysis* / Q000378:metabolism; D014407:Tumor Cells, Cultured
D003432:Cross-Linking Reagents; D008565:Membrane Proteins; D010455:Peptides; D015375:Receptors, Interleukin-2